Cannabis Law Report

SEPTEMBER 2, 2021

Court of Appeals for the Ninth Circuit dismissed a petition brought by a team of cannabis researchers, scientists, and military veterans to require that the Drug Enforcement Administration (DEA) reevaluate marijuana’s status as a Schedule I substance under the Controlled Substances Act (CSA). The case before the Ninth Circuit, Sidley v.

DEA 102

DEA Marijuana Treatment Legalization 102

Veriheal

JUNE 29, 2021

This Act permits individuals that have been diagnosed with life-threatening conditions or diseases that have exhausted all other approved treatment and therapeutic options that are also unable to participate in clinical trials the ability to access certain treatments that would otherwise be unapproved for access.

Therapy 64

Therapy DEA Patients Clinical Trials 64

Cannabis Law Report

JUNE 13, 2022

Only appeals courts may hear challenges to DEA determinations, findings, and conclusions under the Controlled Substances Act, Judge Karen LeCraft Henderson of the US Court of Appeals for the D.C. The DEA in August 2020 issued a rule meant to conform existing regulations to amendments to the CSA in its treatment of hemp.

DEA 52

DEA Hemp Legalization Treatment 52

CannaMD

JULY 19, 2020

Drug Enforcement Agency (DEA) made far fewer cannabis-related arrests in 2019 than in previous years. Let’s take a closer look at what DEA data reveals. But despite all the DEA’s seizing and destroying, it’s clear that the average U.S. That’s what DEA data indicates, at least — especially when looked at closely.

DEA 59

DEA Marijuana Data Decriminalization 59

Canna Law Blog

MARCH 4, 2020

People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. Failure to follow these very specific legal directives can lead to immediate criminal liability under federal law.

Therapy 121

Therapy Legalization Chronic Pain DEA 121

Veriheal

FEBRUARY 23, 2024

As the Drug Enforcement Administration (DEA) and federal government draw closer to moving cannabis from a Schedule I to a Schedule III substance , more groups have begun to put their weight behind the movement. Countless veterans suffer from these ailments, and, as such, are pushing for access to as many treatments and therapies as possible.

DEA 104

DEA Chronic Pain Treatment Therapy 104

FloridaMarijuana.net

JULY 8, 2018

The study has received full approval from the FDA, DEA, and Institutional Review Boards (IRBs). While there is a popular belief that Indica strains are the best treatment, a variety of genetics (Hybrid, Sativa, CBD) may alleviate the symptoms of PTSD. 5 cannabis strains to treat PTSD: 1.

Strains 190

Strains Indica Hybrid Research and Development 190

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). Orphan Drug Designation?

DEA 51

DEA Clinical Trials THC Research and Development 51

SpeedWeed

SEPTEMBER 4, 2021

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. View original article.

DEA 52

DEA Research and Development Clinical Trials Extraction 52

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Cannabis Law Report

FEBRUARY 16, 2022

A 28-page DEA report — authored in August of 2021, and based on Department of Health and Human Services reviews of these psychedelics from 2012 — states, “These five tryptamines have no known medical use in the United States and are not marketed internationally as approved drug products. Read full report at.

DEA 52

DEA Safety Treatment Law 52

CannaMD

NOVEMBER 15, 2020

research on marijuana harms – such as cannabis withdrawal, treatments for substance abuse and use/exposure during pregnancy or infancy – received 20 times more funding than research on cannabis therapeutics. While some funds are being used to study cannabis medical treatments, the majority of funding is still used to research harms.

DEA 106

DEA Clinical Trials Cannabinoids Treatment 106

Cannabis Law Report

JULY 7, 2021

Pennington, who focuses on federal appeals and regulatory issues, is co-counsel on several high-profile cases against the DEA regarding cannabis research, hemp, and psychedelics. Circuit), a pending petition for review of DEA’s August 2020 Interim Final Rule purportedly implementing the 2018 Farm Bill’s amendments to the CSA.

DEA 85

DEA Hemp Cultivation Advocacy 85

Cannabis Law Report

JUNE 12, 2021

MONTEREY, CA – Biopharmaceutical Research Company (BRC), an active Drug Enforcement Administration (DEA) license holder, and CURE Pharmaceutical Holding Corp. CURE has established itself as a leader in the oral application of cannabis-derived treatments, and we know we’ll be able to bring a lot of value to patients together.”.

DEA 45

DEA Pharmaceutical Research and Development Compliance 45

CannaMD

AUGUST 8, 2020

Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. CBD Scheduling Rule Change. But the government is clear. What can CBD do?

CBD 105

CBD DEA Research and Development Hemp 105

Cannabis Law Report

JUNE 10, 2021

(OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company , (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products.

Pharmaceutical 75

Pharmaceutical DEA Research and Development THC 75

CannaMD

NOVEMBER 20, 2020

Making matters worse, there’s only one farm in the entire country with DEA approval to cultivate marijuana for research purposes. On a scale of 1-10, how ironic is it that the most effective treatment for using too much marijuana might be… marijuana? For more details, see: Best Cannabis Disorder Treatment? More Cannabis.

Therapy 104

Therapy Treatment DEA CBD 104

Veriheal

DECEMBER 28, 2021

D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted. Over the last few decades, the cannabis plant and its many components have been the focal point of research and stiff debate.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

Cannabis Law Report

SEPTEMBER 12, 2021

Steve Sisolak signed Assembly Bill 101, making Nevada the first state to legalize the use of cannabinoids as a veterinary treatment. Dr. Dawn Boothe is a professor of veterinary physiology and pharmacology at Auburn University studying cannabis’s potential as a veterinary treatment. Earlier this year, Gov.

Patients 105

Patients Pets Seed-To-Sale Cannabinoids 105

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Drug Enforcement Agency (“DEA”). Id ; 21 CFR 312.1-10; 10; 312.80-88; 88; 312.300 et seq.

Law 81

Law Therapy Clinical Trials Research and Development 81

Veriheal

AUGUST 24, 2022

If passed, the Department of Regulatory Agencies would be required to develop rules that would allow for therapeutic psychedelic programs at licensed healing centers for adults to receive psychedelic treatments by a trained facilitator.

Legalization 111

Legalization Decriminalization Medicine Research and Development 111

MedicalJane

JUNE 29, 2018

The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome. The Next Move Is On The DEA.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Veriheal

APRIL 11, 2022

Drug Enforcement Agency (DEA). According to the company’s CEO, George Hodgin, “federally legal FDA- and DEA-approved cannabis-based drugs will absolutely upend the traditional pharmaceutical market.”. Groff confirmed that it had completed its first batch of medicinal-grade cannabis for research purposes on Feb.

Pharmaceutical 106

Pharmaceutical Research and Development DEA Clinical Trials 106

Veriheal

JULY 23, 2021

ACS Laboratory explains that the DEA states “all synthetically-derived tetrahydrocannabinol remain schedule 1 controlled substance” but the issue here is that they have not “defined what constitutes’ ‘synthetically derived’”. . Is Delta-10 THC Legal? . What do you think? Let us know in the comment section below. .

Cannabinoids 98

Cannabinoids THC Hemp DEA 98

The Fresh Toast

APRIL 17, 2023

5 Facts About Glaucoma And Medical Marijuana Medical marijuana glaucoma treatment can help reduced eye pressure and relieve pain. Here's what you need to know about using cannabis for eye health. The post 5 Facts About Glaucoma And Medical Marijuana appeared first on The Fresh Toast.

Marijuana 98

Marijuana Treatment DEA Topical 98

SpeedWeed

MARCH 28, 2021

The good news is that all groups, including the placebo, showed improvement in PTSD symptoms during the treatment, with the THC group showing the largest response. MAPS has been trying to get approved for a cultivation license for almost 20 years and filed a lawsuit in December 2020 against the DEA. View original article.

Clinical Trials 52

Clinical Trials DEA Treatment THC 52

Veriheal

JUNE 30, 2023

Additionally, participants also reported feeling increased self-awareness and general improvement in relationships following their treatment. Lastly, the guide lays out the complex DEA registration process researchers much navigate to gain access to plants like psilocybin.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Veriheal

MAY 13, 2022

According to the Drug Enforcement Administration (DEA) website , magic mushrooms are recognizable by their slender stems, which are “topped by caps with dark gills on the underside.” Once consumed—whether fresh or dried in the form of a brewed tea or an edible—this hallucinogenic chemical transforms into psilocin.

Research and Development 98

Research and Development Legalization Consumption Microdosing 98

NewsMunchies

NOVEMBER 12, 2021

The problem is, under federal law, psilocybin remains a prohibited Schedule 1 Drug, defined by the DEA as having “no currently accepted medical use and a high potential for abuse.” Today, as mental health awareness grows, there is renewed interest in the use of psychedelics such as psilocybin for the treatment of mental illnesses.

Clinical Trials 90

Clinical Trials Therapy Decriminalization DEA 90

Cannabis Law Report

JULY 1, 2021

In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency recognized psilocybin as a breakthrough therapy for treatment-resistant depression. These designations indicate that psychedelics may represent substantial improvements over existing treatments for mental health conditions.

Law 81

Law Research and Development Therapy DEA 81

The Cannigma

MAY 6, 2021

Other than serving as a lighter version of delta-9-THC, delta-8 has also been researched as a potential treatment for a number of medical conditions and symptoms such as vomiting and nausea, glaucoma, pain, and inflammation. The vast majority of scientific knowledge is based on animal studies, however.

THC 145

THC Cannabinoids Concentrates Hemp 145

Cannabis Law Report

JUNE 20, 2019

Although the use of cannabis is legal for medical and/or recreational use in many states, the United States Drug Enforcement Agency (DEA) continues to classify the whole cannabis plant as a Schedule I controlled substance, which is defined as “drugs with no currently accepted medical use and a high potential for abuse.”

THC 74

THC CBD Oil DEA 74

The Blunt Truth

MARCH 10, 2020

The latter requires extensive vetting , including analyses of the underlying target condition and other related available treatments, conducting a cost benefit analysis from clinical data, as well as strategizing on how drug risks may be identified and mitigated. CBD Class Action Litigation.

CBD 99

CBD Topical Agriculture Hemp 99

Cannabis Law Report

SEPTEMBER 1, 2021

While there has been increasing attention and interest in this issue on Capitol Hill, in the near term the federal tax treatment of cannabis-related business remains fraught with risks. 12] Ultimately, only Congress can amend the CSA itself to remove, or otherwise reform the treatment of cannabis under federal law.

Policy 100

Policy Cannabis Law Treatment 100

Cannabis Law Report

MARCH 2, 2020

Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways ‘ psilocybin therapy for treatment-resistant depression. First up, cannabis has now been scientifically validated as a treatment for two severe forms of childhood epilepsy (more on this in a moment). In 2018, the U.S.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

The Cannigma

MAY 1, 2023

According to the DEA, “substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.” Brain plasticity is basically the brain’s ability to adapt to stress, trauma, and injury. 9 How is ketamine commonly used?

Blood Pressure 98

Blood Pressure Chronic Pain Research and Development Clinical Trials 98

Canna Law Blog

JANUARY 17, 2020

We do know, however, that HR 5587 sends a clear message to the FDA, and to a lesser extent to the USDA, that lawmakers are not pleased with the treatment of hemp. For the USDA, it seems that lawmakers have heard the backlash against the USDA’s testing requirements including the need to test for total THC at DEA-certified labs.

Hemp 111

Hemp CBD Food Cannabinoids 111